Report
A Study of Peluntamig (PT217) in Patients with Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
| العنوان: | A Study of Peluntamig (PT217) in Patients with Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study) |
|---|---|
| المؤلفون: | Hoffmann-La Roche |
| المصدر: | An Open-label, Multicenter, Dose Escalation, and Dose Expansion Phase 1/2 Study with Peluntamig (PT217) Followed by a Key ChemotherapY And/or Checkpoint Inhibitor ComBination in Patients with NeuRoendocrIne Carcinomas That Are Known to Be DLL3 ExpressinG CancErs (SKYBRIDGE) |
| قاعدة البيانات: | ClinicalTrials.gov |
| الوصف غير متاح. |